{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-005352","form_type":"8-K","ticker":"SXTP","cik":"0001946563","company_name":"60 DEGREES PHARMACEUTICALS, INC.","filed_at":"2024-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.356976+00:00","generated_at":"2026-06-06T20:48:55.016872+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Following Jan 17 FDA meeting, 60 Degrees Pharma plans pivotal babesiosis study for tafenoquine","bullets":["FDA Type C meeting on Jan 17, 2024 led to mutual alignment on design of pivotal study for tafenoquine in hospitalized babesiosis.","FDA indicated proposed study could support approval if clinical endpoint used; company revising protocol accordingly.","Patient enrollment targeted to begin in summer 2024 at three northeastern U.S. hospitals.","Tafenoquine (ARAKODA) is FDA-approved for malaria prophylaxis but not yet for babesiosis; estimated 47,000 patients/year in U.S."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-005352","json":"https://secwatch.observer/filing/0001213900-24-005352.json","markdown":"https://secwatch.observer/filing/0001213900-24-005352.md","text":"https://secwatch.observer/filing/0001213900-24-005352.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024005352/0001213900-24-005352-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1946563/000121390024005352/ea191960-8k_60degrees.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T20:48:55.016872+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}